China nod to two Sanofi drugs for rare and complex conditions
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Over 8.8?million Indians aged 60 and above currently live with dementia,
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
Subscribe To Our Newsletter & Stay Updated